Alfred E. Tiefenbacher
TIEFENBACHER PHARMACEUTICALS is a pioneering healthcare company committed to making pharmaceuticals more affordable, available, and better than before. As part of the TIEFENBACHER GROUP, a family-owned enterprise, it develops, manufactures, and registers generic, value-added, and innovative medicines for global markets. The company emphasizes product differentiation, innovation, and a patient-centric approach, with a focus on high-quality medicines across various therapeutic categories and dosage forms. It operates with a strong organizational structure that supports rapid market access, regulatory compliance, and sustainable growth, aiming to improve the lives of millions of patients worldwide. The company has a rich history dating back to 1963, founded by Alfred E. Tiefenbacher, and has evolved through various milestones including the launch of branded pharmaceuticals, establishment of subsidiaries in the USA and India, and the development of innovative drug-eHealth combinations like Oysta. It maintains a global presence in over 80 countries and is driven by a strong entrepreneurial spirit, curiosity, and a commitment to innovation and excellence.
Industries
Nr. of Employees
large (251-1000)
Alfred E. Tiefenbacher
Patents
Products
Finished dosage forms portfolio (>180 products)
A portfolio of finished pharmaceutical products across multiple therapeutic areas and dosage forms available for out-licensing.
Highly potent drug formulations and pipeline
Pipeline and production capability for highly potent drug formulations supported by dedicated containment laboratories and manufacturing blocks.
API distribution and raw material supply (large catalogue)
Global sourcing and distribution network for active pharmaceutical ingredients and raw materials to support internal projects and external customers.
Drug-device combinations and integrated digital health solutions
Combined offerings that integrate drug formulations with delivery devices and digital platforms for personalized dosing and adherence support.
Finished dosage forms portfolio (>180 products)
A portfolio of finished pharmaceutical products across multiple therapeutic areas and dosage forms available for out-licensing.
Highly potent drug formulations and pipeline
Pipeline and production capability for highly potent drug formulations supported by dedicated containment laboratories and manufacturing blocks.
API distribution and raw material supply (large catalogue)
Global sourcing and distribution network for active pharmaceutical ingredients and raw materials to support internal projects and external customers.
Drug-device combinations and integrated digital health solutions
Combined offerings that integrate drug formulations with delivery devices and digital platforms for personalized dosing and adherence support.
Services
Licensing-ready finished pharmaceutical products across therapeutic areas to marketing partners worldwide, supported by dossier preparation and regulatory handover.
On-site GMP manufacturing for small-batch and high-volume production of tablets, capsules and powders, including primary and secondary packaging and batch release.
Consulting and execution support for preparation and submission of marketing authorisation applications, regulatory strategy across jurisdictions, and maintenance of authorisations.
On-site analytical testing, method validation/transfer, stability studies, dissolution profiling and specialized impurity testing to support development, release and regulatory submissions.
Technical transfer of development processes into commercial production including pilot runs, process optimisation and documentation for regulatory compliance.
Global supply chain management including warehousing, import/storage and coordination with marketing partners to enable efficient international launches.
Licensing-ready finished pharmaceutical products across therapeutic areas to marketing partners worldwide, supported by dossier preparation and regulatory handover.
On-site GMP manufacturing for small-batch and high-volume production of tablets, capsules and powders, including primary and secondary packaging and batch release.
Consulting and execution support for preparation and submission of marketing authorisation applications, regulatory strategy across jurisdictions, and maintenance of authorisations.
On-site analytical testing, method validation/transfer, stability studies, dissolution profiling and specialized impurity testing to support development, release and regulatory submissions.
Technical transfer of development processes into commercial production including pilot runs, process optimisation and documentation for regulatory compliance.
Global supply chain management including warehousing, import/storage and coordination with marketing partners to enable efficient international launches.
Expertise Areas
- Finished dosage form development
- Highly potent drug formulation and contained manufacture
- New chemical entity (NCE) discovery and development
- Regulatory submissions and global market access
Key Technologies
- GMP manufacturing operations
- GLP laboratory operations
- X-ray diffraction (XRD) crystallography
- In vitro-in vivo correlation (IVIVC) modelling
News & Updates
The Tiefenbacher Group Football Cup 2025 was won by 'The Lawn Mowers'. Over 200 employees and their families participated in the event.
Germany celebrated Pharmacy Day, and Tiefenbacher Group expressed gratitude to pharmacists for their invaluable contribution.
Tiefenbacher Group achieved a Silver rating in EcoVadis Sustainability ratings, placing it among the top 15% of companies worldwide, recognizing its commitment to CSR in environment, labor, ethics, and sustainable procurement.
The Tiefenbacher Group Football Cup 2025 was won by 'The Lawn Mowers'. Over 200 employees and their families participated in the event.
Germany celebrated Pharmacy Day, and Tiefenbacher Group expressed gratitude to pharmacists for their invaluable contribution.
Tiefenbacher Group achieved a Silver rating in EcoVadis Sustainability ratings, placing it among the top 15% of companies worldwide, recognizing its commitment to CSR in environment, labor, ethics, and sustainable procurement.